Sign in
Taking peopleNo phase

Rosuvastatin plus ezetimibe versus rosuvastatin alone in peripheral artery disease

Compares two cholesterol treatments in people with peripheral artery disease or polyvascular disease.

Key facts

Who runs it
Yonsei University
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Randomized Comparison of Efficacy and Safety of High-intensity Rosuvastatin/Ezetimibe Combination Versus Treat-to-target Rosuvastatin Monotherapy for Patients With Peripheral Artery or Polyvascular Disease (CARE-PVD Trial)
Status
Recruiting
People taking part
2,462 people, planned
Started
22 Apr 2024
Expected to end
6 May 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Combination therapy of high-intensity dose rosuvastatin and ezetimibe
  • Rosuvastatin monotherapy for treat-to-target
Record updated
20 May 2025

Who can take part

The trial is looking for adults with hardened, narrowed leg arteries, or with artery disease in at least two body areas. It compares rosuvastatin plus ezetimibe with rosuvastatin alone.

Age
19 to 80 years
Sex
All sexes
Disease stage
Hardened leg arteries: ankle-brachial index <0.85 with leg pain when walking, or leg artery narrowing of more than 50% on imaging, or past procedure or surgery for leg artery disease. Or at least two of: coronary artery disease; carotid artery narrowing (more than 50%), ischemic stroke or mini-stroke; widened thoracic aorta (>4 cm (1.6 in)) or abdominal aorta (>3cm (1.2 in)).
Earlier treatment
People must take medicine for blood fats, or have LDL cholesterol ≥70 mg/dL (1.8 mmol/L) without taking cholesterol-lowering medicine.
Biomarker or test result
LDL cholesterol ≥70 mg/dL (1.8 mmol/L) if not on cholesterol-lowering medicine; ankle-brachial index <0.85 is one way in.
Main reasons for not taking part
  • Severe lack of blood flow threatening the leg (Rutherford 4~6)
  • Heart attack or similar, stroke, mini-stroke or leg amputation within 6 months
  • Severe kidney problems (eGFR <30 mL/min/1.73m2), dialysis, or solid organ transplant
  • Allergy or serious side effects with statin or ezetimibe; acute liver disease
  • Pregnant, possibly pregnant or breastfeeding women; life expectancy under 3 years
Show the full registry criteria (13)Hide the full registry criteria

Who can take part

  • Ages 19-80
  • Patient with arteriosclerotic lower extremity artery disease or multivessel disease 1) Arteriosclerotic lower extremity artery disease: If any of the following applies; Ankle-brachial index <0.85 with symptoms of intermittent claudication; Lower extremity artery stenosis of more than 50% on imaging tests; History of receiving interventional or surgical treatment for lower extremity artery disease) 2) Arteriosclerotic multivessel disease: When at least two of the following diseases exist even if there is no lower extremity artery disease; Coronary artery disease; History of carotid artery stenosis (more than 50%) or ischemic stroke/transient cerebral ischemia event; degenerative thoracic (maximum diameter >4 cm) or abdominal (maximum diameter >3cm) aortic aneurysm
  • Patients on medication for dyslipidemia or patients with LDL cholesterol level higher than the target level for peripheral arterial disease (≥70 mg/dL) and not on lipid lowering medication

Who cannot take part

  • Solid organ transplant recipients
  • History of acute coronary syndrome or stroke/TIA or lower extremity amputation within 6 months
  • History of allergic or hypersensitivity reaction to statin or ezetimibe or side effects requiring discontinuation of lipid lowering therapy
  • Acute liver disease or persistent unexplained elevation of serum AST or ALT more than twice the upper limit of normal
  • Severe renal dysfunction (eGFR <30 mL/min/1.73m2) or dependancy on dialysis
  • Chronic limb threatening ischemia (Rutherford 4~6)
  • Pregnant women, potentially pregnant or lactating women
  • Life expectancy of less than 3 years
  • When follow-up for more than 1 year is not possible
  • Inability to understand or read the consent form

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Peripheral artery disease or polyvascular disease

This trial is currently available in South Korea.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Patients with atherosclerotic peripheral artery disease often have combined coronary artery disease or cerebral artery disease and show high rates of cardiovascular mortality and morbidities. Therefore, secondary prevention for these patients is of great clinical importance. Currently, Korean, US, and European guidelines recommend different LDL cholesterol target goals in patients with peripheral artery disease. In recent clinical trials, combination therapy of statin plus ezetimibe demonstrated improved cardiovascular outcomes compared with statin monotherapy. Thus, the purpose of the CARE-PVD study is to investigate whether the combination therapy of high intensity rosuvastatin 20 mg plus ezetimibe 10 mg can improve cardiovascular outcomes in patient with peripheral artery disease or polyvascular artery disease in comparison with rosuvastatin treat-to-target (LDL cholesterol <70 mg/dL) monotherapy.

The 2 groups in the trial

  • Rosuvastatin/ezetimibe combination therapyTreatment being tested

    Combination therapy of high-intensity dose rosuvastatin and ezetimibe

    Treatment: Combination therapy of high-intensity dose rosuvastatin and ezetimibe

  • Rosuvastatin monotherapyExisting treatment, for comparison

    Rosuvastatin monotherapy for treat-to-target (LDL cholesterol \< 70 mg/dL)

    Treatment: Rosuvastatin monotherapy for treat-to-target

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Randomized Comparison of Efficacy and Safety of High-intensity Rosuvastatin/Ezetimibe Combination Versus Treat-to-target Rosuvastatin Monotherapy for Patients With Peripheral Artery or Polyvascular Disease (CARE-PVD Trial)
Plain-language title
Rosuvastatin plus ezetimibe versus rosuvastatin alone in peripheral artery diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT06231966, who can take part
Record updated
20 May 2025